Building on previous research, a new study published in Frontiers in Endocrinology evaluated the two-year outcomes associated with a digitally monitored continuous care intervention (CCI) for type 2 diabetes (T2D) patients. The initial findings found that the CCI effectively helped patients achieve nutritional ketosis and thereby improved weight, glycemic outcomes, lipid, and liver marker changes. The present study was an open label, nonrandomized, controlled trial in which T2D patients were stratified by CCI (n = 262) and usual care (n = 87). The primary outcomes were two-year retention, glycemic control, and weight changes. Over the two-year study period, the CCI group presented reduced hemoglobin A1c, fasting glucose, fasting insulin, weight, systolic blood pressure, diastolic blood pressure, triglycerides, and liver alanine transaminase, as well as increased high-density lipoprotein cholesterol. No changes in spine bone mineral density were observed in the CCI group. The CCI group reduced its use of glycemic control medication (with the exception of metformin) from 55.7% to 26.8% (insulin, –62%; sulfonylureas, –100%). With the exception of uric acid and anion gap, the usual care group did not exhibit any of these changes, and diabetes medication use rate did not change. The CCI group also had a 53.5% diabetes reversal rate and 17.6% remission rate; the usual care group did not achieve disease resolution.